Session » Rheumatoid Arthritis – Treatments Poster II: PROs, Safety and Comorbidity
-
Abstract Number: 1511
The Relationship between Lipid Profile Changes and Inflammation across the Phase 3 Sarilumab Rheumatoid Arthritis (RA) Developmental Program
-
Abstract Number: 1512
Reduction in Power Doppler Ultrasound Score with Tocilizumab Treatment Associates with Improvement in the Protective Profile of HDL in Patients with Rheumatoid Arthritis
-
Abstract Number: 1513
Efficacy of Etanercept By Body Mass Index in Women and Men with Rheumatoid Arthritis: A Post Hoc Analysis of Three Randomized Trials
-
Abstract Number: 1514
Impact of Comorbidity Burden and Obesity on the Effectiveness of Tocilizumab in Patients with Rheumatoid Arthritis
-
Abstract Number: 1515
Malignancy in Japanese Patients with Rheumatoid Arthritis Treated with Tofacitinib: Interim Analysis of All-Case Post-Marketing Surveillance
-
Abstract Number: 1516
Infection Events in Japanese Patients with Rheumatoid Arthritis Treated with Tofacitinib: Interim All-Case Post-Marketing Surveillance
-
Abstract Number: 1518
Baricitinib and Tofacitinib in Real Life – Does Obesity Impact Response to Janus Kinase Inhibitor Therapy in Rheumatoid Arthritis?
-
Abstract Number: 1519
Patient Characteristics Associated with Discontinuation of Tofacitinib for the Treatment of Rheumatoid Arthritis in Open-Label, Long-Term Extension Studies up to 9.5 Years
-
Abstract Number: 1520
DMARD Hepatotoxicity in Rheumatoid Arthritis and Its Association with the Surrogates of Metabolic Syndrome
-
Abstract Number: 1521
Anti-IL-6 Therapy Modulates Leptin in Patients with Rheumatoid Arthritis
-
Abstract Number: 1522
Time Dependent Effect of Biologic Therapy on Overall Survival in Patients with Rheumatoid Arthritis and Cancer
-
Abstract Number: 1523
Pain Is Improved in Around 50% of Patients and Fatigue in 40% of Patients with Rheumatoid Arthritis Treated with Sarilumab in the Target, Mobility and Monarch Trials
-
Abstract Number: 1524
Malignancies and Serious Infections in Randomized Controlled Trials of Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
-
Abstract Number: 1525
Effect of JAK-Inhibitor Versus Bdmards on Quality of Life in Rheumatoid Arthritis : A Meta Analysis of Randomized Controlled Trials
-
Abstract Number: 1526
Baseline Characteristics and Outcomes in Patients with Anemia in Clinical Studies of Tofacitinib
-
Abstract Number: 1527
Tofacitinib Improves Left Ventricular Mass and Cardiac Output in Rheumatoid Arthritis Patients with Chronic Heart Failure
-
Abstract Number: 1528
Unique Changes in Hemoglobin with Sarilumab Versus Adalimumab Are Independent of Better Disease Control in Patients with Rheumatoid Arthritis (RA)
-
Abstract Number: 1529
Long-Term, Real-World Safety of Adalimumab in Rheumatoid Arthritis
-
Abstract Number: 1530
CRP Changes during Bacterial Infections in Baricitinib-Treated Patients with RA
-
Abstract Number: 1531
Tofacitinib Show Similar Retention When Used with and without Methotrexate. Analysis from the Rhumadata® Clinical Database and Registry
-
Abstract Number: 1532
Impact of Immunogenicity on Clinical Efficacy and Administration Related Reaction in TNF Inhibitors: A Pooled-Analysis from Three Biosimilar Studies in Patients with Rheumatoid Arthritis
-
Abstract Number: 1533
Simulating Population Disability Outcomes for Alternative Treatment Pathways in Patients with Active Rheumatoid Arthritis
-
Abstract Number: 1534
Comparative Risk of Diabetes Mellitus in Rheumatoid Arthritis Patients Treated with Different Biologics- a Cohort Study
-
Abstract Number: 1535
Enhancing Patient Ability to Process and Use Information about Medication Risks and Benefits
-
Abstract Number: 1536
Mean Platelet Volume Changes with Baricitinib Indicate Reduced New Platelet Production in Baricitinib-Treated Rheumatoid Arthritis Patients
-
Abstract Number: 1537
Frequency and Duration of Early Non-Serious Adverse Events in Rheumatoid Arthritis Patients Treated with Tofacitinib 5 Mg Twice Daily As Monotherapy and Combination Therapy
-
Abstract Number: 1538
Moderate Adverse Drug Reactions Due to Disease Modifying Drugs in a Cohort of Patients with Incident Rheumatoid Arthritis
-
Abstract Number: 1539
Safety of Methotrexate and Leflunomide Combination Therapy in the Treatment of Rheumatoid Arthritis
-
Abstract Number: 1540
Validation of Hepatic Fibrosis Markers in People with Rheumatoid Arthritis on Methotrexate
-
Abstract Number: 1541
The Safety Profile of Iguratimod in Real Clinical Practice: Analysis of 491 Patients with Rheumatoid Arthritis
-
Abstract Number: 1542
Real-World Data from a Post-Approval Safety Surveillance Study of Tofacitinib Vs Biologic Dmards and Conventional Synthetic Dmards: Five-Year Results from a US-Based Rheumatoid Arthritis Registry
-
Abstract Number: 1543
The Efficacy, Safety and Adherence of Biologicbiological Disease-Modifying Anti Rheumatic Drugs, Infliximab, Tocilizumab and Abatacept, in Elderly Patients with Rheumatoid Arthritis
-
Abstract Number: 1544
Tofacitinib Safety and Efficacy in the Treatment of Rheumatoid Arthritis in a Central/Eastern European Subpopulation
-
Abstract Number: 1545
Exploring the Effects of Depressive Symptoms on the Efficacy of Sarilumab and Improvements in Health-Related Quality of Life
-
Abstract Number: 1546
Efficacy and Safety of Corticosteroids in Rheumatoid Arthritis: Systematic Literature Review and Practical Recommendations
-
Abstract Number: 1547
Impact of Obesity on Drug Survival of Tofacitinib in Patients with Rheumatoid Arthritis: Analysis from the Turkbio Registry
-
Abstract Number: 1548
Favorable Effect of Hydroxychloroquine in Patients with Rheumatoid Arthritis and Diabetes or Impaired Glucose Control
-
Abstract Number: 1549
Comparison of Adverse Events and Survival of Treatment in Patients with Rheumatoid Arthritis Receiving Combined Treatment of Methotrexate and Leflunomide Versus Those Receiving Biological Therapy
-
Abstract Number: 1550
Improvement of HbA1c in Patients with Rheumatoid Arthritis and Diabetes Type 2 during Treatment with Tocilizumab
-
Abstract Number: 1551
Anti-Drug Antibodies to Certolizumab Pegol Are Assiciated with Low Drug Levels and Reduced Clinical Response at 3 Months in Patients with Inflammatory Joint Diseases
-
Abstract Number: 1552
No Effect of Concomitant Glucocorticoid Therapy on Efficacy and Safety of Tocilizumab Monotherapy Found in Rheumatoid Arthritis Clinical Trials